Kopran Ltd, a smallcap pharma player with a global passport, makes both APIs and formulations but still struggles with the same question every retail investor asks: “Why is my stock down 47% in one year?” Market cap: ₹881 Cr, CMP: ₹183 (vs a ₹355 high, ouch). The P/E is 25.2—cheap compared to Sun Pharma, but expensive for a company whose PAT just shrank 33% QoQ. ROE at 7.64% is like chai diluted with too much water. Dividend yield? 1.64%, which feels more like pocket money to keep investors from running away.
2. Introduction
In the grand Bollywood drama of Indian pharma, Kopran plays the side character who occasionally gets a dialogue but is mostly there to remind you that smallcaps exist. Founded decades ago, it sells in 50+ countries, makes APIs like Atenolol, and formulations for antibiotics, antihypertensives, and carbapenems. Sounds fancy, right? Except sales growth for five years is just ~12%, slower than Indian trains in monsoon.
Still, Kopran is trying to reinvent itself by merging with its own subsidiary, Kopran Laboratories, to enter diagnostics. Because why just make drugs when you can also make machines to tell people they need drugs? Smart, but will it work? That’s what we’re here to dissect.
3. Business Model – WTF Do They Even Do?
Kopran runs a two-engine business:
API Vertical (via Kopran Research Labs): 26 products, strong in Atenolol (anti-hypertensive), plus carbapenems and macrolides. Basically, raw materials for pharma bros worldwide.
Formulations Vertical: Tablets, syrups, injectables exported to regulated and unregulated markets. 100% export focus makes them sound global, but domestic presence is more “invisible hand.”
Add-ons: They’re merging into diagnostics—machines, reagents, and automation targeting hospitals, tenders, and AIIMS-type institutions. It’s like adding a surprise plot twist halfway through a movie.
Question for you: Do you like companies that stay in their lane, or ones that suddenly open new lanes and drive diagonally?
4. Financials Overview
Source table
Metric
Latest Qtr (Jun’25)
YoY Qtr (Jun’24)
Prev Qtr (Mar’25)
YoY %
QoQ %
Revenue
₹135 Cr
₹139 Cr
₹172 Cr
–3.0%
–21.6%
EBITDA
₹14.1 Cr
₹18.2 Cr
₹17.1 Cr
–22.5%
–17.5%
PAT
₹7.45 Cr
₹11.1 Cr
₹9.68 Cr
–32.9%
–23.0%
EPS (₹)
1.54
2.30
2.01
–33%
–23%
Commentary: Sales down, profits down, margins thinner than cutting chai in Dharavi. Annualized EPS = ~₹6.2 → P/E ~29×. For a company this small, that’s optimism bordering on delusion.
5. Valuation Discussion – Fair Value Range Only
Method 1: P/E Method
Industry avg P/E: ~34.
Kopran EPS TTM = ₹7.24.
Fair value = 20×7.24 (base) to 28×7.24 (optimistic).
